Research programme: neuropeptide Y5 receptor antagonists - EsteveAlternative Names: Neuropeptide Y5 receptor antagonists research programme - Esteve; Obesity therapy research programme - Esteve
Latest Information Update: 19 Jul 2004
At a glance
- Originator Esteve
- Class Benzoxazines
- Mechanism of Action Neuropeptide Y5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 19 Jul 2004 Preclinical trials in Obesity in Spain (unspecified route)